Literature DB >> 11442505

Genomic structure of human FLT3: implications for mutational analysis.

F M Abu-Duhier, A C Goodeve, G A Wilson, R S Care, I R Peake, J T Reilly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11442505     DOI： 10.1046/j.1365-2141.2001.02821.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  17 in total

1.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors:  Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

Review 2.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Sequence alignment by cross-correlation.

Authors:  Alan L Rockwood; David K Crockett; James R Oliphant; Kojo S J Elenitoba-Johnson
Journal:  J Biomol Tech       Date:  2005-12

Review 4.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

5.  Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

Authors:  Mark Levis; Kathleen M Murphy; Rosalyn Pham; Kyu-Tae Kim; Adam Stine; Li Li; Ian McNiece; B Douglas Smith; Donald Small
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

Review 6.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

Review 7.  Emerging therapies for acute myeloid leukemia: translating biology into the clinic.

Authors:  Simon Kavanagh; Tracy Murphy; Arjun Law; Dana Yehudai; Jenny M Ho; Steve Chan; Aaron D Schimmer
Journal:  JCI Insight       Date:  2017-09-21

8.  Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

Authors:  Elly V Barry; Jennifer J Clark; Jan Cools; Johannes Roesel; D Gary Gilliland
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

9.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

Review 10.  Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.